AI speeds molecule screening, but systemic profit models, data inequities, and regulatory bottlenecks still stall equitable drug development
Original framing: “How researchers are using AI to speed up drug discovery and development: Q&A” — Phys.org
AI methods such as deep generative models and reinforcement learning have demonstrably reduced virtual screening time from months to days, yet their predictive validity hinges on high‑quality, bias‑free training data. Reproducibility crises, overfitting, and lack of interpretability remain significant scientific hurdles that must be addressed before clinical translation. Rigorous benchmarking against experimental assays is essential to avoid false optimism.
AI is reshaping the first stage of drug discovery, yet its impact is bounded by entrenched profit motives, data monopolies, and regulatory inertia that perpetuate historic inequities.
By weaving indigenous pharmacological wisdom, cross‑cultural epistemologies, and marginalised patient narratives into open, co‑created data ecosystems, the promise of speed can translate into broader therapeutic relevance. Future‑oriented regulatory reforms and public‑private hubs must embed equitable licensing and benefit‑sharing to prevent a new wave of techno‑colonialism. The trickster insight warns that without disciplined disruption, the veneer of efficiency will conceal deeper systemic biases, making inclusive governance the essential catalyst for genuine transformation.